Fresenius SE KGaA (XTRA:FRE) - Cotización, noticias y análisis

Resumen de acción FRE

Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas.

Acerca de la empresa

FRE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	1/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 48.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 22.7%

Análisis de riesgos

Los pagos de intereses no están bien cubiertos por los beneficios

Los márgenes de beneficio (1.6%) son inferiores a los del año pasado (5.4%)

Competidores de Fresenius SE & Co. KGaA

Fresenius Medical Care

XTRA:FME

€11.0b

SYNLAB

XTRA:SYAB

€2.3b

Carl Zeiss Meditec

XTRA:AFX

€9.0b

Laboratory Corporation of America Holdings

NYSE:LH

US$16.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€27.21
52 Week High	€31.22
52 Week Low	€23.93
Beta	1.08
1 Month Change	8.84%
3 Month Change	2.14%
1 Year Change	3.78%
3 Year Change	-33.77%
5 Year Change	-45.83%
Change since IPO	2,310.11%

Noticias y actualizaciones recientes

Recent updates

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Is Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?

Jan 13

Here's Why Fresenius SE KGaA (ETR:FRE) Has A Meaningful Debt Burden

Dec 29

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Dec 14

At €41.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Oct 15

Is Fresenius SE KGaA (ETR:FRE) A Risky Investment?

Sep 30

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Sep 15

Is Now The Time To Look At Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 17

Fresenius SE KGaA (ETR:FRE) Takes On Some Risk With Its Use Of Debt

Jul 01

There Are Reasons To Feel Uneasy About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jun 14

Should Shareholders Reconsider Fresenius SE & Co. KGaA's (ETR:FRE) CEO Compensation Package?

May 15

Rentabilidad de los accionistas

	FRE	DE Healthcare	Mercado DE
7D	-0.6%	-1.6%	1.2%
1Y	3.8%	-3.9%	2.0%

Rentabilidad vs. Industria: FRE superó al sector German Healthcare , que obtuvo un rendimiento del -3.9% el año pasado.

Rentabilidad vs. Mercado: FRE superó al mercado German, que obtuvo un rendimiento del 2.2% el año pasado.

Volatilidad de los precios

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement	3.3%
Healthcare Industry Average Movement	6.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: FRE no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de FRE (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1912	193,865	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, una empresa de asistencia sanitaria, ofrece productos y servicios para pacientes con enfermedades crónicas. Opera a través de cuatro segmentos: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios y Fresenius Vamed. El segmento Fresenius Medical Care ofrece productos y servicios para pacientes con insuficiencia renal crónica.

Resumen de fundamentos de Fresenius SE & Co. KGaA

¿Cómo se comparan los beneficios e ingresos de Fresenius SE KGaA con su capitalización de mercado?
Estadísticas fundamentales de FRE
Capitalización bursátil	€15.33b
Beneficios(TTM)	€353.00m
Ingresos (TTM)	€22.30b

43.4x

Ratio precio-beneficio (PE)

0.7x

Ratio precio-ventas (PS)

¿Está FRE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de FRE
Ingresos	€22.30b
Coste de los ingresos	€17.24b
Beneficio bruto	€5.06b
Otros gastos	€4.71b
Beneficios	€353.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 08, 2024

Beneficios por acción (BPA)	0.63
Margen bruto	22.68%
Margen de beneficio neto	1.58%
Ratio deuda/patrimonio	70.4%

¿Cómo se ha desempeñado FRE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción FRE

Recompensas

Análisis de riesgos

Competidores de Fresenius SE & Co. KGaA

XTRA:FME

€11.0b

XTRA:SYAB

€2.3b

XTRA:AFX

€9.0b

NYSE:LH

US$16.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Recent updates

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Price target decreased to €40.39

Second quarter 2022 earnings: EPS misses analyst expectations

Healius Reportedly Launches Day Surgery Sale Process